Back to news

Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026

Business Wire•19/11/2026•06:59 ET
0

Key Highlights

  • ➤Bristol Myers Squibb will present more than 90 hematology disclosures, including 24 oral presentations
  • ➤Phase 3 EXCALIBER-RRMM reports PFS and MRD results for ZENBEXUS in relapsed/refractory myeloma
  • ➤Five-year TRANSFORM follow-up evaluates Breyanzi's potential for curative treatment in second-line large B-cell lymphoma
  • ➤Phase 1 data advance dual-targeting tunlucabtagene autoleucel in relapsed/refractory multiple myeloma
  • ➤Phase 2 GOLSEEK-2 results evaluate golcadomide plus rituximab in newly diagnosed follicular lymphoma

Expert Statements

Cristian Massacesi, Executive vice president, chief medical officer and head of development, Bristol Myers Squibb

“This has been an extraordinary year across our blood cancer portfolio, and what we’re sharing at ASH is the realization of our scientific investments.”

Cristian Massacesi, Executive vice president, chief medical officer and head of development, Bristol Myers Squibb

“At ASH, we’re highlighting the breadth of our work in blood cancers from Phase 3 CELMoD datasets in multiple myeloma, exploration of targeted protein degradation’s potential in follicular lymphoma, five-year landmark survival data for Breyanzi and the clinical potential of our dual-targeted CAR T, tunlucabtagene autoleucel.”

Cristian Massacesi, Executive vice president, chief medical officer and head of development, Bristol Myers Squibb

“Together, these advancements reflect one goal: to move beyond the current standard management of blood cancers and redefine what patients can expect from treatment.”

Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026

CELMoD programs advance across multiple myeloma and lymphoma, with Phase 3 readouts for ZENBEXUS™ (iberdomide) and mezigdomide, and Phase 2 data for golcadomide

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in